Oncobiologics Inc  

(Public, NASDAQ:ONS)   Watch this stock  
Find more results for ONS
-0.02 (-1.66%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.17 - 1.19
52 week 0.78 - 3.52
Open 1.17
Vol / Avg. 684.00/48,332.00
Mkt cap 30.13M
P/E     -
Div/yield     -
EPS -1.69
Shares 25.74M
Beta     -
Inst. own 15%

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin -219.79% -1019.26%
Operating margin -89.67% -941.36%
EBITD margin - -870.73%
Return on average assets -135.15% -168.40%
Return on average equity - -
Employees 48 -
CDP Score - -


7 Clarke Dr
CRANBURY, NJ 08512-3627
United States - Map
+1-609-6193990 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).

Officers and directors

Pankaj Mohan Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Lawrence A. Kenyon Chief Financial Officer, Corporate Secretary
Age: 52
Bio & Compensation  - Reuters
Scott A. Gangloff Senior Vice President - Development and Manufacturing
Age: 43
Bio & Compensation  - Reuters
Stephen J. McAndrew Ph.D. Senior Vice President - Business Strategy & Development
Age: 63
Bio & Compensation  - Reuters
Kogan Bao Ph.D. Vice President - Analytical Sciences
Age: 47
Bio & Compensation  - Reuters
Elizabeth A. Yamashita Vice President - Regulatory Affairs
Age: 56
Bio & Compensation  - Reuters
Kenneth M. Bahrt M.D. Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
Claudio Albrecht Director
Bio & Compensation  - Reuters
Yezan Haddadin Director
Bio & Compensation  - Reuters
Scott A. Canute Independent Director
Age: 57
Bio & Compensation  - Reuters